News
Celon Pharma will present results of its research on esketamine and the PDE10A inhibitor at the 31st European College of Neuropsychopharmacology Congress in Barcelona
During the three days of the congress, more than 6,000 participants from all over the world: psychiatrists, psychologists and neurologists, will discuss the most important scientific reports in the field of diagnosis and treatment of brain diseases, from primary research to clinical development. Representatives of the Oncology Research Group will present three poster session topicsRead more »
Celon Pharma on Esketamine at the 3rd Central European Biomedical Congress (CEBC)
Representatives of the Celon Pharma Neuropsychiatry Research Group took part in the 3rd Central European Biomedical Congress (CEBC) which was held on 15-18 September this year. This is the largest scientific conference dedicated to preclinical research and biomedical sciences in our part of Europe. The theme of this year’s edition was, among others, neuropsychiatry. DuringRead more »
Celon Pharma enhances its platform for the development of biotechnology drugs
The company has established substantive cooperation with Pure Biologics S.A., a biopharmaceutical company. The two entities will cooperate in the field of research and development on biotechnological drugs, which will result in the identification of potential biotech drug candidates, which Celon Pharma will subsequently be developing in preclinical and clinical areas. Maciej Wieczorek, PhD, CEORead more »
The Management Board’s notice on the voluntary and preventive discontinued marketing of Valzek
Information of the Management Board of Celon Pharma S.A. Nationwide voluntary and preventive withholding of Valzek (80 mg and 160 mg). With regard to the decisions of the Chief Pharmaceutical Inspector, on 21 August 2018 the Board of the Celon Pharma S.A. announces that the decisions had been issued at the Company’s request. The undertakenRead more »
Information of the Management Board of Celon Pharma S.A. Nationwide voluntary and preventive withholding of Valzek (80 mg and 160 mg).
With regard to the decisions of the Chief Pharmaceutical Inspector, on 21 August 2018 the Board of the Celon Pharma S.A. announces that the decisions had been issued at the Company’s request. The undertaken actions constitute a response to a global market situation regarding the active ingredient valsartan.. These steps are preventive in nature and areRead more »
Notice of Celon Pharma S.A.’s Management Board on repealing the decision on temporary withholding of one Salmex batch (batch no.: 223020018)
Information of the Management Board of Celon Pharma S.A.. The Management Board of Celon Pharma S.A. announced that on 10 August 2018 the Chief Pharmaceutical Inspector repealed its decision No. 4/WS/2018 of 21.06.2018 on the voluntary, temporary withholding of one batch of Salmex, (500 µg + 50 µg), number 223020018. The results of tests conducted onRead more »
Researchers from Celon Pharma S.A.’s R&D Centre publish their article in the prestigious European Journal of Medicinal Chemistry
At the end of May, the prestigious scientific journal European Journal of Medicinal Chemistry published an article of researchers from our R&D Division: Rafał Moszczyński-Petkowski, Jakub Majer, Małgorzata Borkowska, Łukasza Bojarski, Sylwia Janowska, Mikołaj Matłoka, Filip Stefaniak, Damian Smuga, Katarzyna Bazydło, Krzysztof Dubiel and Maciej Wieczorek. The publication’s subject is: Synthesis and characteristics of two newRead more »
The application for a consent to commence phase II of a clinical trial on an Esketamine-based drug has been submitted
On 20 June 2018, Celon Pharma S.A. has submitted an application to the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products for the consent to commence the next stage of the trial, i.e. the clinical phase. A decision in this matter should be issued within 60 days. The second phase of clinicalRead more »
Celon Pharma S.A. at the American Diabetes Association’s 78th Scientific Sessions
On 24 June 2018, representatives of Celon Pharma’s Metabolic Disorders Research Group will take part in a poster session, during which they will make a presentation on the following subject: Discovery of CPL207-280ca, an effective and safe GPR40 agonist for the treatment of type 2 diabetes. The conference is the world’s largest event bringing together researchers,Read more »